PARP inhibition

Interviews and expert commentary tagged “PARP inhibition” — the latest oncology research and clinical practice from the Audio Journal of Oncology.

First Line PARP Inhibition For Ovarian Cancer Assessed
Audio Journal of Oncology

First Line PARP Inhibition For Ovarian Cancer Assessed

MUNICH—The role of poly ADP ribose polymerase (PARP) inhibitors for treating newly diagnosed advanced ovarian cancer was under review at the 2018 annual congress of the European Society for Medical On

2 November 2018
7 Minutes
BRCA1/2 Ovarian Cancer—Three Years Disease Free with First-Line Olaparib
Audio Journal of Oncology

BRCA1/2 Ovarian Cancer—Three Years Disease Free with First-Line Olaparib

BRCA1/2 Ovarian Cancer—Three Years Disease Free with First-Line Olaparib MUNICH—An “unprecedented improvement” in progression free survival (PFS) was observed in the randomized controlled

1 November 2018
8 mins
← Browse all episodes